Sophiris Bio Stock Forecast, Price & News

0.00 (0.00 %)
(As of 05/6/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume35,911 shs
Average Volume337,178 shs
Market Capitalization$753,660.00
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SPHS News and Ratings via Email

Sign-up to receive the latest news and ratings for Sophiris Bio and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:SPHS
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Market Cap$753,660.00
Next Earnings DateN/A
OptionableNot Optionable


Sophiris Bio Inc (SPHS)
Sophiris Bio Inc (SPHS)
October 24, 2020 |  nasdaq.com
Sophiris Bio, Inc. (SPHS)
Sophiris Bio, Inc. (SPHS)
August 19, 2020 |  ca.finance.yahoo.com
Sophiris Bio To Shut Down Operations
Sophiris Bio To Shut Down Operations
May 18, 2020 |  finance.yahoo.com
Sophiris Bio Inc.
Sophiris Bio Inc.
April 25, 2020 |  www.barrons.com
Sophiris to delist; shares plummet 42% after hours
Sophiris to delist; shares plummet 42% after hours
March 10, 2020 |  seekingalpha.com
Sophiris Bio Announces Nasdaq Delisting
Sophiris Bio Announces Nasdaq Delisting
March 10, 2020 |  finance.yahoo.com
SPHS Feb 2020 2.500 call
SPHS Feb 2020 2.500 call
February 22, 2020 |  finance.yahoo.com
See More Headlines

About Sophiris Bio

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.


Overall MarketRank

0.13 out of 5 stars

Medical Sector

1843rd out of 2,041 stocks

Pharmaceutical Preparations Industry

729th out of 769 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Sophiris Bio (OTCMKTS:SPHS) Frequently Asked Questions

What stocks does MarketBeat like better than Sophiris Bio?

Wall Street analysts have given Sophiris Bio a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sophiris Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Sophiris Bio?

Sophiris Bio saw a drop in short interest in April. As of April 15th, there was short interest totaling 3,400 shares, a drop of 55.8% from the March 31st total of 7,700 shares. Based on an average daily volume of 172,000 shares, the short-interest ratio is presently 0.0 days.
View Sophiris Bio's Short Interest

How were Sophiris Bio's earnings last quarter?

Sophiris Bio, Inc. (OTCMKTS:SPHS) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.08) EPS for the quarter, topping the Zacks' consensus estimate of ($0.10) by $0.02.
View Sophiris Bio's earnings history

How has Sophiris Bio's stock price been impacted by COVID-19?

Sophiris Bio's stock was trading at $0.23 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SPHS stock has decreased by 90.8% and is now trading at $0.0212.
View which stocks have been most impacted by COVID-19

Who are Sophiris Bio's key executives?

Sophiris Bio's management team includes the following people:
  • Mr. Randall E. Woods, Pres, CEO & Director (Age 69, Pay $537.28k)
  • Dr. Samuel R. Denmeade, Chief Scientific Officer & Member of the Scientific Advisory Board
  • Dr. James Joseph Beesley, Sr. Director of Investor Relations (Age 49)
  • Mr. Iain R. Mant, Corp. Sec.

Who are some of Sophiris Bio's key competitors?

What is Sophiris Bio's stock symbol?

Sophiris Bio trades on the OTCMKTS under the ticker symbol "SPHS."

How do I buy shares of Sophiris Bio?

Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sophiris Bio's stock price today?

One share of SPHS stock can currently be purchased for approximately $0.02.

How much money does Sophiris Bio make?

Sophiris Bio has a market capitalization of $753,660.00.

How many employees does Sophiris Bio have?

Sophiris Bio employs 6 workers across the globe.

What is Sophiris Bio's official website?

The official website for Sophiris Bio is www.sophirisbio.com.

Where are Sophiris Bio's headquarters?

Sophiris Bio is headquartered at 1258 PROSPECT STREET, LA JOLLA CA, 92037.

How can I contact Sophiris Bio?

Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The company can be reached via phone at 858-777-1760 or via email at [email protected]

This page was last updated on 5/7/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.